NovaBay Pharmaceuticals, a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that in tests conducted at a third-party laboratory, NovaBay’s lead Aganocide, NVC-422 has shown in vitro activity against the “superbug” New Delhi Metallo-beta-lactamase-1 (NDM-1)-encoded Klebsiella pneumoniae at a very low concentration of 2 microgram per milliliter.

H. Lundbeck A/S (Lundbeck) announced the completion of two out of three pivotal studies in the phase III clinical programme for nalmefene in alcohol dependence (ESENSE1 and SENSE). The studies were conducted in Europe and enrolled about 1,300 patients with alcohol dependence. A concomitant psychosocial intervention in the studies was a brief, standardised programme focussed on adherence and follow-up. No abstinence treatment goals were imposed.

Innovate in an era of cost-effectiveness: Realise the value of personalised medicine

  • Discover how to strengthen your drug pipeline with companion diagnostics
  • How to access the market
  • Hear about the expectation of the pharmaceutical and diagnostics industry and payors
  • Discover how pharmaceutical companies and diagnostics companies can work together successfully